Time filter

Source Type

Weide R.,Praxisklinik fur Hamatologie und Onkologie Koblenz | Feiten S.,Institute For Versorgungsforschung In Der Onkologie Invo | Friesenhahn V.,Institute For Versorgungsforschung In Der Onkologie Invo | Heymanns J.,Praxisklinik fur Hamatologie und Onkologie Koblenz | And 4 more authors.
Deutsche Medizinische Wochenschrift | Year: 2015

Background: Infections are major complications in chronic lymphoproliferative disorders, among them indolent non-Hodgkin's lymphoma (iNHL) including chronic lymphocytic leukemia, follicular lymphoma and multiple myeloma. We report on a retrospective cohort analysis of outpatients with indolent non-Hodgkin's lymphoma who were treated in an oncology / hematology group practice and received intravenous polyvalent immunoglobulin G (IVIG) as supportive care. The aim was to describe the treated iNHL population, the course of therapy and the effects of IVIG administrations on the levels of immunoglobulin G (IgG), the incidence of infections and the survival time. Patients and Method: 57 patients with secondary iNHL antibody deficiencies (n = 46) or IgG subclass deficiencies (n = 11) who received IVIG substitution were included. Patients received median 11 IVIG doses with a mean dose of 28 g over a period of median 9.5 months. Results: Mean IgG levels increased with IVIG substitution at about twice and then remained within the normal range. The incidence of infections decreased in 46 % of treated patients. Effects on survival could not be observed. Median overall survival was in the group of substituted patients 124 months (range 7-124), the control group had a median survival time of 96 months (range 3-129) (p = 0.537). Conclusion: IgG levels should be reviewed during IVIG substitution on a regular basis and dosage and intervals should be adjusted individually. © Georg Thieme Verlag KG Stuttgart New York.


PubMed | Institute For Versorgungsforschung In Der Onkologie Invo and Praxisklinik fur Hamatologie und Onkologie Koblenz.
Type: Journal Article | Journal: Deutsche medizinische Wochenschrift (1946) | Year: 2015

Infections are major complications in chronic lymphoproliferative disorders, among them indolent non-Hodgkins lymphoma (iNHL) including chronic lymphocytic leukemia, follicular lymphoma and multiple myeloma.We report on a retrospective cohort analysis of outpatients with indolent non-Hodgkins lymphoma who were treated in an oncology/hematology group practice and received intravenous polyvalent immunoglobulin G (IVIG) as supportive care. The aim was to describe the treated iNHL population, the course of therapy and the effects of IVIG administrations on the levels of immunoglobulin G (IgG), the incidence of infections and the survival time.57 patients with secondary iNHL antibody deficiencies (n=46) or IgG subclass deficiencies (n=11) who received IVIG substitution were included. Patients received median 11 IVIG doses with a mean dose of 28g over a period of median 9.5 months.Mean IgG levels increased with IVIG substitution at about twice and then remained within the normal range. The incidence of infections decreased in 46% of treated patients. Effects on survival could not be observed. Median overall survival was in the group of substituted patients 124 months (range 7-124), the control group had a median survival time of 96 months (range 3-129) (p=0.537).IgG levels should be reviewed during IVIG substitution on a regular basis and dosage and intervals should be adjusted individually.

Loading Institute For Versorgungsforschung In Der Onkologie Invo collaborators
Loading Institute For Versorgungsforschung In Der Onkologie Invo collaborators